ADULT STUDY DESIGNS

DUPIXENT was evaluated in adult patients whose moderate-to-severe atopic dermatitis
was inadequately controlled on topical Rx therapies^1,2,a

Disease severity was defined by an IGA score ≥3 in the overall assessment of atopic dermatitis lesions on a severity scale of 0 to 4, an EASI score ≥16 on a scale of 0 to 72, and a minimum body surface area involvement of ≥10%.¹

Primary endpoint across all 3 adult pivotal trials: Change from baseline to Week 16 in the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and a ≥2-point improvement¹

	Adult (18+ years of age)1,2
Number of patients	>2100
Pivotal trialsb	2 Monotherapy (Trials 1 and 2) 1 Concomitant TCS (Trial 3)
Dosagec	An initial dose of 600 mg DUPIXENT at Week 0 followed by 300 mg Q2Wd
Disease severity at baseline Moderate atopic dermatitis (IGA 3)	52%
Severe atopic dermatitis (IGA 4)	48%
Disease extent at baseline Mean EASI score	33 out of 72
Mean body surface area involvement	55%
Itch severity at baselinee Peak Pruritus NRS	7 out of 10

Adult clinical trials included monotherapy (Trials 1 and 2) and with concomitant TCS (Trial 3); all trials initiated with two 300 mg DUPIXENT or placebo subcutaneous injections at Week 0, and emollient background regimen was required.¹

Treatment effects in subgroups in Trials 1, 2, and 3 were generally consistent with the results in the overall adult study population^1,f

Weight

Age

Gender

Race

Prior treatment, including
immunosuppressants

See Peak Pruritus NRS Results
See EASI Results
See IGA Results

EASI, Eczema Area and Surface Index: IGA, Investigator’s Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; TCS, topical corticosteroids.

^aThese baseline characteristics are not meant for comparison.

^bTrial 4 was a dose‑ranging trial to evaluate the safety of DUPIXENT monotherapy through Week 16. Trial 5 evaluated multiple DUPIXENT monotherapy dose regimens for maintaining treatment response for 36 weeks.

^cEmollient background regimen was required.

^dStudied vs placebo.

^eWeekly averaged Peak Pruritus NRS score (10 indicates the most severe).

^fSubgroup analysis was based on all 3 adult trials.